In summary, PBF509 demonstrated remarkable potential in experimental animal models of movement disorders, including PD and LID, thus becoming an excellent candidate for clinical A2AR-based treatment of PD motor symptoms. This evidence concerns the gene ADORA2A and movement disorder.